Dive Brief:
- Senseonics and Sequel Med Tech have launched a Type 1 diabetes system that combines their glucose monitoring and insulin delivery technologies, the companies said Thursday.
- The system, which was originally due to launch in the third quarter of 2025, pairs Senseonics’ Eversense 365 continuous glucose monitor with Sequel’s automated insulin delivery system.
- Sequel’s twiist is the first AID technology to integrate with the one-year CGM implant, enabling Senseonics to offer an alternative to automated systems based on Abbott’s and Dexcom’s sensors.
Dive Insight:
Competitors Abbott and Dexcom have integrated their CGMs with insulin delivery systems from companies including Beta Bionics, Insulet and Tandem Diabetes Care. FreeStyle Libre 3 Plus, an Abbott sensor, is also authorized to work with Sequel’s twiist.
The integrations support various combinations of sensors and pumps, but all the systems are based on wearable CGM patches that last 15 days at most. Eversense 365 is an implant that lasts one year. When Senseonics won Food and Drug Administration clearance for the device in 2024, it received an integrated CGM designation that supports use with AID systems.
In April 2025, Senseonics partnered with Sequel to integrate Eversense 365 and twiist. When they struck the deal, Senseonics and Sequel planned to launch the system in the third quarter of 2025. The expected launch date had moved to the fourth quarter by August. It had slipped again by November, when Senseonics said it was “actively working towards the integration of the companies’ products to be completed in the fourth quarter of 2025 and available to consumers shortly thereafter.”
Senseonics CEO Tim Goodnow said on an earnings call in November that Sequel needed to complete “some scaling activities” before the launch. Goodnow said some large customers were very interested in the system, but “there does need to be enough capacity on the pump side to support all of that.”
The company reported in January that the first commercial patients had started using the system. With the launch underway, attention will now turn to the system’s impact on Senseonics’ sales, which grew 57% to $35.2 million last year, according to preliminary results. Dexcom, a rival CGM specialist, reported sales of $4.7 billion last year.
Goodnow said the integrated system could drive top-line growth for Senseonics in 2026. However, the CEO also warned that sales “may be gated by the pump availability” for the first couple of quarters before supply improves later in 2026.
